Developer docs
API playgroundTry for free, no card

Search company profiles

MIG Capital

Full company profile

uuid0007jqt

Namestring
MIG Capital
Legal namestring
MIG Capital AG
Websiteurl
mig.ag
Company typeenum
Private
Founded yearint
2004
Descriptiontext

MIG Capital AG is a Munich-based venture capital firm founded in 2004 that invests in early to mid-stage Deep Tech and Life Sciences companies primarily across Europe. The firm operates through MIG Fonds, a series of 18 publicly offered retail-VC funds (MIG Fonds 2 through 18) that are 100% subscribed by private investors in Germany and Austria — making MIG the only retail-accessible VC platform of its kind in Germany under KAGB regulation. MIG Capital deploys €1-10 million per deal (with a €3-5 million sweet spot) from seed through Series A, targeting deep tech themes (advanced computing, quantum, IoT, energy, new materials) and life sciences (biopharmaceuticals, medical devices, digital health).

The firm is not a technology developer; its product is capital plus active portfolio support, strategic guidance, and network access delivered through an interdisciplinary team of engineers, biologists, physicists, lawyers, and investors. Its revenue model is conventional for VC: recurring management fees on ~€1.3 billion of committed capital, supplemented by episodic carried interest from exits. To date, MIG Capital has backed 57 companies, holds 32 active positions, and has realized 25 trade-sale exits and 4 IPOs (BioNTech, BRAIN, NFON, Immatics), with BioNTech alone distributing ~€600 million to fund investors.

Recent portfolio activity demonstrates continued diversification into space traffic management (Look Up), AI photonic semiconductors (NcodiN), industrial solar thermal (GlassPoint), and biotech (SciRhom, TIBEAY, iOmx, mbiomics), alongside exits in 2025 including biocrates to Bruker, wealthpilot, creativeballoons, and the insolvency of German Bionic.

Short descriptiontext

MIG Capital AG is a Munich-based venture capital firm founded in 2004 that invests early-to-mid-stage capital from 18 publicly offered MIG Fonds into Deep Tech and Life Sciences startups across Europe, serving both portfolio companies and retail limited partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMünchen, Germany
HQ citystring
München
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, deep tech investments, life sciences funding, retail venture funds, early stage equity
Industry1 code
1Sector-Focused Venture Capital (Vertical Specialists)
CodeFSANAAADPrimaryYes
NAICS code2 codes
  • Other Financial Vehicles52599
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital Investment Management
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees
TypeSubscription Recurring
Description

VC firms typically charge annual management fees on committed capital from their fund investors (limited partners).

mig.ag
2Carried Interest
TypeTransaction Fee
Description

MIG Capital generates returns through carried interest (performance fees) when portfolio companies are exited at gains. Notable exits include BioNTech (distributed ~600M EUR total to investors), Siltectra (sold to Infineon), and Hemovent (sold to MicroPort).

mig.ag
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

MIG Capital is a Munich-based venture capital firm that invests early to mid-stage equity capital in Deep Tech and Life Sciences companies, primarily in German-speaking Europe and beyond. Through its MIG Fonds (18 publicly accessible retail VC funds), it provides ticket sizes of EUR 1-10M (sweet spot EUR 3-5M) from seed through Series A, along with active portfolio support, strategic guidance, and international network access. The firm also earns carried interest from successful portfolio exits such as BioNTech, Siltectra, Hemovent, and others.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • EUR 600 million distributed to investors from BioNTech exit alone
+3 more records
Product overview1 text field

MIG Capital is a Munich-based venture capital firm that invests in innovative Deep Tech and Life Sciences companies across Europe through its MIG Fonds (publicly accessible retail VC funds). MIG Capital does not develop or offer its own technology products or services; rather, it provides investment capital, expertise, and network access to portfolio companies developing innovations in biopharmaceuticals, quantum computing, AI hardware, digital health, medical devices, and sustainable technologies. The MIG Fonds are the firm's primary investment vehicle, offering retail investors access to early-stage venture capital investments with a focus on seed to Series B stages.

Product and service3 records
1MIG Fonds (Retail VC Funds)
CategoryVenture Capital Fund Vehicle
Description

Publicly accessible retail venture capital funds (currently 18 MIG Fonds) that pool private investor capital for deployment into MIG Capital's portfolio of Deep Tech and Life Sciences companies. Managed by MIG Capital AG under German KAGB regulation with a designated depositary bank.

2Deep Tech Equity Investment Program
CategoryEquity Investment Program
Description

Equity investment offering targeting early-stage startups in advanced computing (AI, quantum computing), industrial IoT, robotics, automation, sustainable energy, and novel materials. Typical ticket sizes EUR 1-10M with sweet spot EUR 3-5M from seed through Series A, with active portfolio support and international expansion network.

3Life Sciences Equity Investment Program
CategoryEquity Investment Program
Description

Equity investment offering for biopharmaceutical, medical technology, and digital health startups. Investment focus covers oncology, autoimmune diseases, brain trauma, microbiome therapeutics, hearing technologies, and related fields. Ticket sizes EUR 1-10M with active portfolio support and pharmaceutical partnership network access.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Hauck Aufhäuser Lampe Privatbank AG
Strategic tierCustodianTypeOthers
Description

Designated depositary bank (Verwahrstelle) for MIG Capital's funds as required by German KAGB regulation.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment97 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MIG Capital

Venture Capital Investment Managementmig.ag

MIG Capital AG is a Munich-based venture capital firm founded in 2004 that invests early-to-mid-stage capital from 18 publicly offered MIG Fonds into Deep Tech and Life Sciences startups across Europe, serving both portfolio companies and retail limited partners.

What MIG Capital does

MIG Capital AG is a Munich-based venture capital firm founded in 2004 that invests in early to mid-stage Deep Tech and Life Sciences companies primarily across Europe. The firm operates through MIG Fonds, a series of 18 publicly offered retail-VC funds (MIG Fonds 2 through 18) that are 100% subscribed by private investors in Germany and Austria — making MIG the only retail-accessible VC platform of its kind in Germany under KAGB regulation. MIG Capital deploys €1-10 million per deal (with a €3-5 million sweet spot) from seed through Series A, targeting deep tech themes (advanced computing, quantum, IoT, energy, new materials) and life sciences (biopharmaceuticals, medical devices, digital health).

The firm is not a technology developer; its product is capital plus active portfolio support, strategic guidance, and network access delivered through an interdisciplinary team of engineers, biologists, physicists, lawyers, and investors. Its revenue model is conventional for VC: recurring management fees on ~€1.3 billion of committed capital, supplemented by episodic carried interest from exits. To date, MIG Capital has backed 57 companies, holds 32 active positions, and has realized 25 trade-sale exits and 4 IPOs (BioNTech, BRAIN, NFON, Immatics), with BioNTech alone distributing ~€600 million to fund investors.

Recent portfolio activity demonstrates continued diversification into space traffic management (Look Up), AI photonic semiconductors (NcodiN), industrial solar thermal (GlassPoint), and biotech (SciRhom, TIBEAY, iOmx, mbiomics), alongside exits in 2025 including biocrates to Bruker, wealthpilot, creativeballoons, and the insolvency of German Bionic.

MIG Capital firmographics

Firmographics
Name
MIG Capital
Legal name
MIG Capital AG
Website
https://mig.ag
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
MIG Capital AG is a Munich-based venture capital firm founded in 2004 that invests early-to-mid-stage capital from 18 publicly offered MIG Fonds into Deep Tech and Life Sciences startups across Europe, serving both portfolio companies and retail limited partners.
Ownership category
akta.pro rank

MIG Capital industry classification

Industry
Product category
Venture Capital Investment Management
NAICS
Other Financial Vehicles (52599), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro primary industry
Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

  • Venture capital investing
  • Deep tech investments
  • Life sciences funding
  • Retail venture funds
  • Early stage equity

Where MIG Capital is headquartered

Location

Headquarters

HQ city
München
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

MIG Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Management Fees: VC firms typically charge annual management fees on committed capital from their fund investors (limited partners).
  2. Carried Interest: MIG Capital generates returns through carried interest (performance fees) when portfolio companies are exited at gains. Notable exits include BioNTech (distributed ~600M EUR total to investors), Siltectra (sold to Infineon), and Hemovent (sold to MicroPort).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

MIG Capital product offering

Product offering

Core offering

MIG Capital is a Munich-based venture capital firm that invests early to mid-stage equity capital in Deep Tech and Life Sciences companies, primarily in German-speaking Europe and beyond. Through its MIG Fonds (18 publicly accessible retail VC funds), it provides ticket sizes of EUR 1-10M (sweet spot EUR 3-5M) from seed through Series A, along with active portfolio support, strategic guidance, and international network access. The firm also earns carried interest from successful portfolio exits such as BioNTech, Siltectra, Hemovent, and others.

Product overview

MIG Capital is a Munich-based venture capital firm that invests in innovative Deep Tech and Life Sciences companies across Europe through its MIG Fonds (publicly accessible retail VC funds). MIG Capital does not develop or offer its own technology products or services; rather, it provides investment capital, expertise, and network access to portfolio companies developing innovations in biopharmaceuticals, quantum computing, AI hardware, digital health, medical devices, and sustainable technologies. The MIG Fonds are the firm's primary investment vehicle, offering retail investors access to early-stage venture capital investments with a focus on seed to Series B stages.

Differentiator

Problem solved

Functional benefit

Products and services

  • MIG Fonds (Retail VC Funds) Publicly accessible retail venture capital funds (currently 18 MIG Fonds) that pool private investor capital for deployment into MIG Capital's portfolio of Deep Tech and Life Sciences companies. Managed by MIG Capital AG under German KAGB regulation with a designated depositary bank.
  • Deep Tech Equity Investment Program Equity investment offering targeting early-stage startups in advanced computing (AI, quantum computing), industrial IoT, robotics, automation, sustainable energy, and novel materials. Typical ticket sizes EUR 1-10M with sweet spot EUR 3-5M from seed through Series A, with active portfolio support and international expansion network.
  • Life Sciences Equity Investment Program Equity investment offering for biopharmaceutical, medical technology, and digital health startups. Investment focus covers oncology, autoimmune diseases, brain trauma, microbiome therapeutics, hearing technologies, and related fields. Ticket sizes EUR 1-10M with active portfolio support and pharmaceutical partnership network access.

Quantifiable outcome

  • EUR 600 million distributed to investors from BioNTech exit alone
  • +3 more outcomes

Companies that use MIG Capital

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles3 records

MIG Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

MIG Capital partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

Scale indicators10 records

Recent moves12 records

Expansion highlights4 records

MIG Capital competitors and assessment

Company assessment

Market position

Weaknesses3 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

MIG Capital social profiles

Digital presence

MIG Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MIG Capital leadership team

Management profile

Number of profiles

Profiles9 records

MIG Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MIG Capital M&A and investment

M&A and investment

M&A

Investments97 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MIG Capital

What does MIG Capital do?

MIG Capital is a Munich-based venture capital firm that invests early to mid-stage equity capital in Deep Tech and Life Sciences companies, primarily in German-speaking Europe and beyond. Through its MIG Fonds (18 publicly accessible retail VC funds), it provides ticket sizes of EUR 1-10M (sweet spot EUR 3-5M) from seed through Series A, along with active portfolio support, strategic guidance, and international network access. The firm also earns carried interest from successful portfolio exits such as BioNTech, Siltectra, Hemovent, and others.

Is MIG Capital a public or private company?

MIG Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was MIG Capital founded?

MIG Capital was founded in 2004. It employs 11 to 50 people.

Where is MIG Capital based?

MIG Capital is headquartered in München, Germany, in the Europe region.

How does MIG Capital make money?

Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.

Does MIG Capital have an API?

No public API is recorded for MIG Capital.

What industry is MIG Capital in?

MIG Capital's product category is Venture Capital Investment Management. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52599 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartbaseLuffy AI Raises 8.1 Million Pounds – MIG Capital Invests in AI for Real-Time Industrial ControlBritish deep tech startup Luffy AI has secured £8.1 million in Series A funding to develop neuroplastic AI technology for real-time industrial control of machines such as electric motors and variable-frequency drives. The round was led by BGF with participation from MIG Capital, Bow Capital, Chrysalix, Momenta, and UKI2S, with MIG Capital investing £1.5 million through its MIG Funds 2, 6, and 18. The company plans to use the capital to accelerate the transition from pilot projects to industrial deployment and expand strategic partnerships with leading industrial companies.FinanzNachrichten.deMIG Capital beteiligt sich über ihre MIG Fonds an der Series-A-Finanzierungsrunde über 8,1 Mio. £ des britischen Startups Luffy AIMIG Capital, a German venture capital firm, participated in an £8.1 million Series-A financing round for Luffy AI, a UK-based deep tech startup headquartered in Abingdon, contributing £1.5 million through its MIG Funds 2, 6, and 18. The funding round was led by BGF and included existing investors Bow Capital, Chrysalix, Momenta, and UKI2S. Luffy AI develops neuroplastic AI for adaptive real-time control in industrial applications, with its technology claiming to be up to 400 times more efficient than conventional deep learning, and the funding will be used to accelerate commercialization and convert proof-of-concepts into strategic partnerships with industrial companies.StartupmagLuffy AI raises £8.1m in series A led by BGF with MIG CapitalLuffy AI raised £8.1m in a Series A led by BGF, with participation from MIG Capital and others. The funding will commercialize its neuroplastic AI stack for energy-efficient motor control, targeting industrial applications. The company aims to scale pilots with industrial partners.BusinessCloudLuffy AI, founded by nuclear physicists, raises £8.1mLuffy AI raised £8.1 million in a Series A round led by BGF, with participation from MIG Capital and existing investors. The firm's neuroplastic AI stack claims up to 400x efficiency over traditional deep learning for industrial motor control. Funding will drive commercialization and partnerships with industry brands.Tech.euLuffy secures £8.1M to scale real-time adaptive control technologyLuffy AI, a UK-based startup developing AI for real-time adaptive control in industrial systems, has raised £8.1 million in a Series A funding round led by BGF, with participation from MIG Capital AG, Bow Capital, Chrysalix, Momenta and UKI2S. The company has developed a neuroplastic AI platform using sparse neural networks trained in simulation and refined during operation, enabling real-time adaptive control for industrial motors without large datasets or cloud-based retraining. The funding will be used to convert proof-of-concept projects and pilot deployments into long-term partnerships with industrial customers while supporting broader rollout of the technology into applications including robotics, drones and thermal process control.BitlyLuffy secures £8.1M to scale real-time adaptive control technologyLuffy AI, a UK-based startup developing AI for real-time adaptive control in industrial systems, has raised £8.1 million in a Series A funding round led by BGF with participation from MIG Capital AG and existing investors Bow Capital, Chrysalix, Momenta, and UKI2S. The company's neuroplastic AI platform enables industrial motors and physical systems to adapt in real time without relying on large datasets, continuous cloud connectivity, or extensive computing resources. The funding will be used to convert proof-of-concept projects and pilot deployments into long-term commercial partnerships while supporting broader rollout of the technology across industrial motor control, robotics, and other physical AI applications.FinanzNachrichten.deMIG Fonds: Beteiligungsunternehmen IQM geht an die Börse in New YorkIQM Quantum Computers, a Finnish-German quantum computing company headquartered in Espoo and Munich, completed its Nasdaq listing on Thursday following a merger with US-SPAC Real Asset Acquisition Corp., with trading beginning on Nasdaq Helsinki the following day. The transaction valued IQM at approximately 1.6 billion euros pre-IPO, making it the first leading European quantum computing company to go public. MIG Capital, which invested in IQM as a founding investor in 2008 through multiple funds, announced the milestone as a significant step for European technological sovereignty.Startuprad.io Startup PodcastAndreas von Bechtolsheim and Germany: The Bavarian Who Quietly Funds European Deep TechAndreas von Bechtolsheim, a German-born co-founder of Sun Microsystems and Arista Networks, is the 5th wealthiest German with a net worth of $31.4–35.4 billion, derived from his ~15–17% Arista stake. He funds DACH deep-tech companies like KONUX and Black Semiconductor, and his SEC insider-trading settlement in 2024 is the only major controversy.FinSMEsGlassPoint Raises $20M in FundingGlassPoint, a NYC-based solar industrial process heat company, raised $20M in funding led by N.I.S. New Investment Solutions with participation from returning investor MIG Capital. The company plans to expand its Technology Center in Stuttgart, Germany, and hire business development, engineering, and finance talent in Dubai and the United States. GlassPoint provides solar-thermal technology that generates solar steam to replace natural gas in heavy industries like mining and metals.GlobeNewswireMIG Capital leads CHF 7.75 million seed financing for ASTRA TherapeuticsMIG Capital led a CHF 7.75 million seed financing for ASTRA Therapeutics, with Digitalis Ventures co-leading and Borealis Ventures, Kickfund, and Venture Kick participating. The Swiss start-up designs precision drugs against eukaryotic pathogens, targeting a global parasiticide market worth over $10 billion. The investment marks MIG Capital's first Swiss investment and second new investment this year.